Matinas BioPharma
MTNB
47 hedge funds and large institutions have $3.37M invested in Matinas BioPharma in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 8 closing their positions.
0% more ownership
Funds ownership: 0.24% → 0.24% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
8% less funds holding
Funds holding: 51 → 47 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
64% less capital invested
Capital invested by funds: $9.31M → $3.37M (-$5.93M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$185K |
| 2 |
Squarepoint
New York
|
+$36.4K |
| 3 |
Renaissance Technologies
New York
|
+$16.8K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$10.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.51K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Courage Capital Management
Nashville,
Tennessee
|
-$119K |
| 2 |
SCA
STALEY CAPITAL ADVISERS
Pittsburgh,
Pennsylvania
|
-$49.1K |
| 3 |
VF
Virtu Financial
New York
|
-$33K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$28.2K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$24.6K |
MTNB Hedge Fund Activity: Q3 2023 in Review
47 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2023, worth a combined $3.37M — down 64% from $9.31M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MTNB and 4 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $185K. The largest seller was Courage Capital Management, exiting entirely with an estimated $119K sold.
- 47 institutional investors held Matinas BioPharma (MTNB) as of Q3 2023, down from 51 in Q2 2023.
- Funds reported $3.37M of Matinas BioPharma stock for Q3 2023, down 64% quarter-over-quarter.
- 4 funds opened new Matinas BioPharma positions in Q3 2023 and 8 closed out, a net change of -4 holders.
- The largest Matinas BioPharma buyer in Q3 2023 was Jacobs Levy Equity Management, an estimated $185K added.
- The largest Matinas BioPharma seller in Q3 2023 was Courage Capital Management, an estimated $119K sold.
Based on aggregated 13F filings for Q3 2023.